Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402Phase 2Active, not recruiting
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Mar 2023
- Primary completion
- Mar 2028
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of povetacicept in lupus nephritis (LN), immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Alpine Immune Sciences, Inc.. Started Mar 2023; status: active, not recruiting.
02
Drugs
povetacicept
03
Conditions
lupus nephritis (LN)immunoglobulin A nephropathy (IgAN)membranous nephropathy (MN)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05732402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732402.